PE - 医索

找到约 1072 条结果

Trastuzumab and pertuzumab in combination witheribulin mesylate or a taxane as first-linechemotherapeutic treatment for HER2-positive, locallyadvanced or metastatic breast cancer results of amulti

医客学院 - 会议报告集

SACI-0 HR A randomized phase ll trial ofsacituzumab govitecan with or without pembrolizumabin patients with metastatic hormone receptor-positive!HER2-negative breast cancer

医客学院 - 会议报告集

ECOG-ACRIN EAZ171 Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TlPN) in Black women with early-stage breast cancer

医客学院 - 会议报告集

DESTINY-Breast07dose-expansion analysis ofT-DXd monotherapy and T-DXd pertuzumab inpatients with previously untreated HER2 mBC

医客学院 - 会议报告集

Datopotamab deruxtecan (Dato-DXd)vs chemotherapy inpreviously-treated inoperable or metastatic hormonereceptor-positive, HER2-negative (HR HER2-) breast cancerPatient-reported outcomes(PROs) from

医客学院 - 会议报告集

ACE-Breast-02 a pivotal phase lllll trial of ARX788, anovel anti-HER2 ADC, vs lapatinib plus capecitabine forHER2 advanced breast cancer

医客学院 - 会议报告集

A Randomized, Multicenter, Open-label, Phase lll Trial ComparingAnthracyclines Followed by Taxane Versus Anthracyclines Followedby Taxane Plus Carboplatin as (Neo) Adjuvant Therapy in Patientswith

医客学院 - 会议报告集

Phase lalb trial of zongertinib (Bl 1810631),aHER2-specific tyrosine kinase inhibitor in patients withHER2 aberration-positive solid tumors updatedPhase la data from Beamion LUNG-1, includingprogression-

医客学院 - 会议报告集

Outcomes with Perioperative Durvalumab in Patientswith Resectable NSCLc and Baseline N2 Lymph NodeInvolvement(N2 R-NSCLC)

医客学院 - 会议报告集

Managing Expectations WithAntibody-Drug Conjugates in Non-Small Cell Lung Cancer

医客学院 - 会议报告集

今日实时热搜